SG11201811806TA - Prophylactic or therapeutic agent for organ fibrosis - Google Patents

Prophylactic or therapeutic agent for organ fibrosis

Info

Publication number
SG11201811806TA
SG11201811806TA SG11201811806TA SG11201811806TA SG11201811806TA SG 11201811806T A SG11201811806T A SG 11201811806TA SG 11201811806T A SG11201811806T A SG 11201811806TA SG 11201811806T A SG11201811806T A SG 11201811806TA SG 11201811806T A SG11201811806T A SG 11201811806TA
Authority
SG
Singapore
Prior art keywords
cell
prophylactic
organ fibrosis
therapeutic agent
fibrosis
Prior art date
Application number
SG11201811806TA
Inventor
Mari Dezawa
Michiaki Unno
Toshihiro Yamamoto
Yasuhiro Shindo
Hiroto Hara
Naoya Masutomi
Original Assignee
Univ Tohoku
Life Science Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tohoku, Life Science Institute Inc filed Critical Univ Tohoku
Publication of SG11201811806TA publication Critical patent/SG11201811806TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

PROPHYLACTIC OR THERAPEUTIC AGENT FOR ORGAN FIBROSIS An object of the present invention is to provide a safe and easy-to-prep cell product for prevention and/or treatment of organ fibrosis such as liver fibrosis. Provided is a 5 cell product for prevention and/or treatment of organ fibrosis such as liver fibrosis, the cell product comprising a SSEA-3-positive pluripotent stem cell (Muse cell) derived from mesenchymal tissue in a living body or a cultured mesenchymal cell. [FIG. 4] 10
SG11201811806TA 2016-07-01 2017-06-30 Prophylactic or therapeutic agent for organ fibrosis SG11201811806TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016132075 2016-07-01
PCT/JP2017/024246 WO2018003997A1 (en) 2016-07-01 2017-06-30 Prophylactic or therapeutic agent for organ fibrosis

Publications (1)

Publication Number Publication Date
SG11201811806TA true SG11201811806TA (en) 2019-02-27

Family

ID=60786047

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811806TA SG11201811806TA (en) 2016-07-01 2017-06-30 Prophylactic or therapeutic agent for organ fibrosis

Country Status (9)

Country Link
US (1) US20190201455A1 (en)
EP (1) EP3479833B1 (en)
JP (2) JPWO2018003997A1 (en)
KR (1) KR102513507B1 (en)
CN (1) CN109689073A (en)
AU (1) AU2017287529B2 (en)
CA (1) CA3029505A1 (en)
SG (1) SG11201811806TA (en)
WO (1) WO2018003997A1 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008140141A1 (en) * 2007-05-16 2008-11-20 Rnl Bio Co., Ltd. Pharmaceutical composition for preventing and treating liver fibrosis or hepatic cirrhosis comprising mesenchymal stem cell
WO2008148105A1 (en) * 2007-05-25 2008-12-04 Medistem Laboratories, Inc. Endometrial stem cells and methods of making and using same
US9550975B2 (en) 2009-07-15 2017-01-24 Mari Dezawa SSEA-3 pluripotent stem cell isolated from body tissue
US9420307B2 (en) * 2011-09-23 2016-08-16 Qualcomm Incorporated Coding reference pictures for a reference picture set
WO2014027474A1 (en) * 2012-08-17 2014-02-20 株式会社Ｃｌｉｏ Pluripotent stem cell that induces repair and regeneration after myocardial infarction
WO2014089397A1 (en) * 2012-12-06 2014-06-12 Aastrom Biosciences, Inc. Compositions and methods of treating and preventing pulmonary fibrosis
WO2014123930A2 (en) * 2013-02-05 2014-08-14 Williams Joseph L Prevention and treatment of tissue fibrosis
WO2016054155A1 (en) * 2014-09-30 2016-04-07 Primegen Biotech, Llc. Treatment of fibrosis using deep tissue heating and stem cell therapy

Also Published As

Publication number Publication date
CA3029505A1 (en) 2018-01-04
EP3479833B1 (en) 2023-11-01
AU2017287529A1 (en) 2019-02-14
WO2018003997A1 (en) 2018-01-04
CN109689073A (en) 2019-04-26
AU2017287529B2 (en) 2022-11-10
KR20190026772A (en) 2019-03-13
JPWO2018003997A1 (en) 2019-04-25
US20190201455A1 (en) 2019-07-04
EP3479833A1 (en) 2019-05-08
EP3479833A4 (en) 2020-02-26
KR102513507B1 (en) 2023-03-22
JP2023001294A (en) 2023-01-04

Similar Documents

Publication Publication Date Title
PH12017501342A1 (en) Glycan therapeutics and related methods thereof
MX2018004616A (en) Cosmetic composition having probiotic bacteria.
MX2020005100A (en) Cultivation of placenta to isolate exosomes.
EP2608797A4 (en) Bone marrow derived cd271 precursor cells for cardiac repair
MX2020012018A (en) Compositions for the treatment of skin conditions.
WO2018143552A3 (en) Injectable composition for preventing hair loss or stimulating hair growth
GB2535937A (en) Methods and compositions for modulating the immune system with Arginase I
WO2014141210A3 (en) Multifunctional immature dental pulp stem cells and therapeutic applications
MX2016016756A (en) Stem cell therapy in endometrial pathologies.
WO2018220489A3 (en) Methods of obtaining cells from human postpartum umbilical cord arterial tissue
MX2021001036A (en) Botanical and bacterial extracts displaying retinol-like activity.
MX2020003762A (en) Cosmetic compositions and method of treating the skin.
MX2018008645A (en) 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives.
NZ745184A (en) 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
PH12017502403A1 (en) Musk composition and methods of use thereof
AU2017260532A1 (en) Methods and devices for preparation of ultrasound contrast agents
MX2021012041A (en) Methods of promoting thymic epithelial cell and thymic epithelial cell progenitor differentiation of pluripotent stem cells.
MX2022004373A (en) Modified stem cells and methods of use thereof.
PH12021550122A1 (en) Solubilized apyrases, methods and use
SG11201900796UA (en) Prophylactic or therapeutic agent for vascular disorder
WO2018200481A8 (en) Methods of making improved human intestinal organoid compositions via application of strain and human intestinal organoid compositions thereof
MX2019014867A (en) Method for treating a side effect of immunotherapy.
SG10201710666UA (en) Pharmaceutical composition to be used for treatment of infertility and method for producing same
WO2012070032A3 (en) Composition and method to improve the therapeutic effect of stem cells
PH12017500743A1 (en) Tau protein production accelerator, and therapeutic or preventive agent and therapeutic or preventive food composition for diseases caused by tau protein deficiency